Where does Exosome Diagnostics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Exosome Diagnostics, Inc. ranks #15,265 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Exosome Diagnostics, Inc. hold?

Exosome Diagnostics, Inc. holds 19 US utility patents granted between 2019 and 2025, spanning 8 technology areas.

What is Exosome Diagnostics, Inc.'s Innovation Score?

Exosome Diagnostics, Inc. has an Innovation Score of 39.1 out of 100 (top 39% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Exosome Diagnostics, Inc.'s patent grant rate increasing or decreasing?

Exosome Diagnostics, Inc.'s recent grant velocity is +333% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Exosome Diagnostics, Inc.'s patents?

Exosome Diagnostics, Inc.'s patents average 12.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Exosome Diagnostics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Exosome Diagnostics, Inc.

Q: What technology areas does Exosome Diagnostics, Inc. focus on?

Exosome Diagnostics, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 12 patents. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 19 granted patents across 8 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Exosome ranks #15,265 of 50,000 tracked US assignees by granted-patent volume, with 19 patents across 8 technology areas.

#15,265
of 50,000 US assignees by volume: Top 39%
by Innovation Score (39.1/100): 12.7
avg claims per patent: +333%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15265 · US Corporation #15,265 · 19 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 19 grants
MID-PACK #15,265/50,000
PHOTO-FINISH Esurance Insurance S…
CPC-NARROW C12Q · 8 areas
INNOV-THIN 39.1/100
CLAIMS-RICH 12.7 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +333% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Esurance Insurance Services, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Axell · near

39
Exosome Diagnostics · this assignee

39
Micronas · near

39
Morpho Detection · near

39
Shutterstock · near

39
3D Lighting Innovati… · lowest

7

What this shows Exosome Diagnostics, Inc. stamps GRANTS-MICRO, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-RICH, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #15,265 of 50,000; Innovation Score 39.1/100 sits in the top 39% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Esurance Insurance Services, Inc. (±0 grants).

Portfolio overview

Exosome Diagnostics, Inc. has been granted 19 US utility patents between 2019 and 2025, placing Exosome Diagnostics, Inc. at #15,265 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.7 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Exosome Diagnostics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Exosome sits between Esurance Insurance Services, Inc. (19 patents, rank #15,261) and Fermentalg (19 patents, rank #15,269) - the closest US assignees by grant volume. The composite Innovation Score of 39.1/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 13 grants, compared with 3 in the 2015–2019 window, a +333% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Exosome Diagnostics, Inc.'s 12.7 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Esurance Insuranc…

19
Eternal East (HK)

19
Evolved Wireless

19
Exal

19
F Smit Holding B V

19
Faurecia Automoti…

19
FCX Solar

19
Fermentalg

19
Exosome Diagnosti… ◀

19

What this shows Exosome holds 19 patents at rank #15,265, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Exosome

By rank, the assignees closest to #15,265 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Exosome's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Exosome, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Morpho Detection, Llc 39 Micronas Gmbh 39 Axell Corporation 39 Shutterstock, Inc. 39

Exosome's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 39% higher than 61% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Exosome Diagnostics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	3	15.8%
2020	1	5.3%
2021	2	10.5%
2022	7	36.8%
2024	3	15.8%
2025partial year	3	15.8%

Which technologies does Exosome Diagnostics, Inc. patent most?

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 12

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 12

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 3

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 2

B01D - SEPARATION 2

G16B - BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY 1

B01L - CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE 1

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#15,265

of 50,000 tracked assignees

Innovation Score

39.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.